KRAS is the most commonly mutated oncogene in human cancer, with mutations present in approximately 20% of all human cancers, and mutationally activated RASgenes have been thought to be the main cause of resistance in several cancers, impacting multiple cellular processes that are critical to tumor progression [27]. This evidence concerns the gene KRAS and cancer.